Exploiting T-cell therapy is emerging as one of the most effective treatment options to combat malignancies.However, which subset and functional quality of CD8+ T cells is more suitable for achieving effective and durable responses in the strong immunosuppressive context of cancer is still a matter of debate and investigation.We detected recently that in average 25％ of human memory CD8+ T cells express CD40L, a strong immunostimulatory molecule of activated CD4+ T helper cells that is even able to overcome cancer-induced immunosuppression.Therefore, we analyzed the role of this distinct CD8+ T-cell population in antitumor responses.